Physiology and Pharmacology (Due 24 hours)

Topic: Ubrelvy

Thesis statement: Ubrelvy is used in the treatment of migraine. It works by altering the level of certain natural substances contained in the human brain. It assists relieve pain, headache, and other migraine symptoms such as vomiting and nausea.

Introduction

A. Use of Ubrelvy – when to use Ubrelvy and conditions managed through the use of this medication.

B. Benefits of this medication in managing each specific symptom

C. Key terms: Dosage, Carcinogenesis, Mutagenesis, Pharmacokinetics

D. Pharmacodynamics, Lactation, and administration

Abstract

Ubrelvy is one of the medicines used to lessen how often an individual gets migraines or prevents future migraines. This medication should be taken by mouth as directed by a medical healthcare professional. It is also taken at the first sign of a migraine. Dosage to different people is based on treatment, medical conditions, and other medication that a patient could be taking (Elliott & Chan, 2020). Therefore, this paper seeks to examine medicines through the use of Ubrelvy to different relevant health conditions. The paper will highlight prescribing information for the drug. The highlight includes considerable information on what the patient and the healthcare professional should know before using UBRELVY effectively and safely (Singh et al. 2020). An individual should not take more than 200 milligrams of Ubrelvy within 24 hours. Therefore, a patient should be a medical professional if they are not sure of when or if it is safe for them to take a second dose of Ubrelvry. It is not clear if a person should take this medication for more than eight migraines within 30 days (Young, 2020). The use of Ubrelvy is not recommended for migraine preventive treatments. However, the paper agrees with the recommendation of Unrelvy in the treatment of acute migraine with or without aura in adults.

I. Background:

A. Overview: Approximately 12 percent of the world population, including 10 percent of children, experience migraines (Young, 2020). They affect 6 percent of American men and 18 percent of American women. Accumulatively, a total of 4 million people experience daily chronic migraines and experience this kind of migraine 15 days a month. There exist several medications for migraine, among them Ubrelvy (Elliott & Chan, 2020)

B. Clinical studies

II. Dosage and administration

A. Dosage Modifications

B. Recommended Dosage

III. Contraindications: Specific situations in which the medication should not be used because it may have harmful effects on the patient.

IV. Drug interactions: Takes place when the medication reacts with another prescribed one. This may result in unexpected side effects.

A. BCRP and P-gp Only Inhibitors

B. CYP3A4 Inhibitors

C. CYP3A4 Inducers

V. Clinical pharmacology

A. Pharmacokinetics

B. Pharmacodynamics

C. Mechanism of Action

VI. Medication use in specific populations

A. Pediatric Use

B. Hepatic Impairment

C. Pregnancy

D. Geriatric Use

E. Renal Impairment

VII. Adverse reactions: Clinical Trials Experience

VIII. Overdosage – when the medication is taken in more than the recommended amount. What are the implications of overdose?

IX. Nonclinical toxicology

A. Animal Toxicology

B. Carcinogenesis, Impairment of Fertility, Mutagenesis

X. Patient counseling information

XI. Conclusion

A. Restatement of Thesis: Ubrelvy is used in the treatment of migraine. It assists relieve pain, headache, and other migraine symptoms such as vomiting and nausea.

References

Elliott, W., & Chan, J. (2020). Ubrogepant Tablets (Ubrelvy). Internal Medicine Alert, 42(3).

Young, C. A. (2020). The first-in-class drug provides acute pain relief for migraine sufferers. Pharmacy Today, 26(3), 17.

Singh, A., Gupta, D., & Sahoo, A. K. (2020). Acute migraine: can the new drugs clinically outpace. SN Comprehensive Clinical Medicine, 2(8), 1132-1138.